- Myomectomy, a surgical procedure for removing uterine fibroids while preserving the uterus, is gaining traction as a preferred treatment among women seeking fertility preservation and minimally invasive options for managing fibroid-related symptoms in both hospital and ambulatory settings
- The rising demand for myomectomy procedures is largely driven by increasing awareness of reproductive health, higher incidence of uterine fibroids, and growing preference for uterus-sparing treatments among women of reproductive age
- North America dominated the myomectomy market with the largest revenue share of 39.5% in 2024, supported by advanced healthcare infrastructure, high diagnostic rates, and a strong presence of leading surgical device manufacturers, with the U.S. experiencing significant procedural volumes due to early adoption of robotic-assisted and laparoscopic surgeries
- Asia-Pacific is expected to be the fastest growing region in the myomectomy market during the forecast period due to improving access to healthcare, increasing medical tourism, and rising awareness of fibroid-related treatment options
- Laparoscopic myomectomy segment dominated the myomectomy market with a share of 46.1% in 2024, driven by patient preference for minimally invasive approaches offering reduced recovery time, lower complication rates, and shorter hospital stays
